Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.